About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 11538 record(s)
Req # A-2020-000022
List of all individuals and their positions granted approval by the Minister to enter Canada under powers granted via Orders-in-Council, since March 26, 2020.Organization: Health Canada
April 2020
Req # A-2019-000619
Adverse Reaction Report (AER) for FLUDARABINE PHOSPHATE. Report numbers: E2B_02197586, E2B_02105492, E2B_02000196, E2B_02071543.Organization: Health Canada
April 2020
Req # A-2019-001185
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_01892334 , E2B_01892365 , 000713989, E2B_01848290 , 000714254 , E2B_01814996, E2B_01848759, E2B_01851055, E2B_01853462, E2B_01823780, E2B_01869202 ,E2B_01874767,…Organization: Health Canada
April 2020
Req # A-2019-001260
Adverse Reaction Report (AER). Report numbers: E2B_02611193, E2B_02624461, E2B_02624807, E2B_02624863, E2B_02635358.Organization: Health Canada
April 2020
Req # A-2019-001376
Adverse Reaction Report (AER) for leflunomide. Report numbers: 722158, E2B_00438018, E2B_01173673, E2B_01329857, E2B_01579808, E2B_02012072, E2B_02045745, E2B_02046051, E2B_02047645, E2B_02051341, E2B_02050601, E2B_02052618, E2B_02066790,…Organization: Health Canada
April 2020
Req # A-2019-001500
Adverse Reaction Report (AER) for ONDANSETRON. Report numbers: E2B_02435087, E2B_02450564, E2B_02453386, E2B_02710741, E2B_02453388, E2B_02483652, E2B_02483653, E2B_02483654, E2B_02483694, E2B_02486232, E2B_02489109, E2B_02489630, E2B_02506132,…Organization: Health Canada
April 2020
Req # A-2019-001595
Adverse Reaction Report (AER) for DEXLANSOPRAZOLE. Report number: E2B_02752874.Organization: Health Canada
April 2020
Req # A-2019-001599
Adverse Reaction Report (AER) for ONDANSETRON. Report numbers: 000729490, E2B_02743135.Organization: Health Canada
April 2020
Req # A-2019-001626
Adverse Reaction Report (AER) for Singulair. Report number: E2B_00218368. AER for Temodal. Report numbers: 000614955, 2B_00199440, E2B_00199477. AER for Varivax II. Report number: 000629992. AER for Vasotec. Report numbers: 000625156, 000643791. AER…Organization: Health Canada
April 2020
Req # A-2019-001628
Adverse Reaction Report (AER). Report numbers: E2B_02677382, E2B_02658115.Organization: Health Canada
April 2020